CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0822 (clinicaltrials.gov NCT No: NCT01410630)
Title:FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Principal Investigator:Luis E. Fayad
Treatment Agent:Cyclophosphamide; Doxorubicin; FDGPET; FLT-PET; Prednisone; Rituximab; Vincristine
Study Status:Open
Study Description:The goal of this clinical research study is to compare a new kind of imaging
scan solution (called F-fluorothymidine (FLT) solution) with the current
standard F- fluorodeoxyglucose (FDG) solution during positron emission
tomography (PET)/computed tomography (CT) scans when used in patients with
DLBCL who are receiving chemotherapy.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:N/A
Treatment Agents:Cyclophosphamide
Doxorubicin
FDGPET
FLT-PET
Prednisone
Rituximab
Vincristine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:NIH
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Luis E. Fayad
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults